“…We examined this hypothesis, first using a reliable animal model of narcolepsy, the orexin-/-mouse, which displays DREMs, a characteristic symptom of the disease (Chemelli et al, 1999;Mignot, 2005;Fujiki, et al, 2006), then in narcoleptic patients, by testing the effects of tiprolisant (BF2.649), a potent and selective inverse agonist of the H3 receptors (Ligneau et al, 2007a and2007b) in both proof-of-concept studies. This class of agents is known to promote wakefulness by inhibiting the constitutively active H3-autoreceptor, thereby enhancing histaminergic neuron activity and histamine (HA) release (Schwartz et al, 1991;Lin, 2000;Morisset et al, 2000;Vanni-Mercier et al, 2003;Parmentier et al, 2002Parmentier et al, , 2007.…”